AZPIL rises on entering into distribution agreement with Dr Reddy’s Laboratories

01 Jun 2015 Evaluate

Astrazeneca Pharma India is currently trading at Rs. 974.00, up by 11.75 points or 1.22% from its previous closing of Rs. 962.25 on the BSE.

The scrip opened at Rs. 966.00 and has touched a high and low of Rs. 997.25 and Rs. 965.35 respectively. So far 5365 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1245.00 on 23-Jun-2014 and a 52 week low of Rs. 785.30 on 17-Dec-2014.

Last one week high and low of the scrip stood at Rs. 1015.85 and Rs. 850.00 respectively. The current market cap of the company is Rs. 2440.25 crore.

The promoters holding in the company stood at 75.00 %, while Institutions and Non-Institutions held 15.69% and 9.31% respectively.

AstraZeneca Pharma India (AZPIL) and Dr Reddy’s Laboratories have entered into a distribution agreement for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and distributed in the Indian market.

Onglyza (saxagliptin), AstraZeneca’s patented therapy, is an oral hypoglycemic (anti-diabetic therapy) in the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.

Dr. Reddy’s Laboratories will be distributing Riax and Riax M in India. This partnership strengthens Dr. Reddy’s diabetes franchise in India. It enables AstraZeneca to expand usage of this molecule through wider reach to physicians and benefiting more number of diabetic patients.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

Astrazeneca Pharma I Share Price

9211.50 22.60 (0.25%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×